Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Jazz Pharmaceuticals plcJAZZ · Entity 818 | EVP & Chief Legal Officer | September 10, 2026 | September 14, 2026 |
| TELEFLEX INCTFX · Entity 3798 | Director | May 15, 2026 | May 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Jazz Pharmaceuticals plc
Report date September 10, 2026 · Filed September 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 47,671 |
Reported balance
After 2026-09-10 transaction · row 1
1 source rowRow 1 · 2026-09-10 · Sale · Disposed 1,200 · Balance 47,671 F1: This transaction was made pursuant to a plan adopted by the reporting person on February 26, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was made pursuant to a plan adopted by the reporting person on February 26, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.
TELEFLEX INC
Report date May 15, 2026 · Filed May 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,716 |
Reported balance
After 2026-05-15 transaction · row 1
1 source rowRow 1 · 2026-05-15 · Grant · Acquired 1,090 · Balance 3,716 F1: Restricted Stock Unit Award granted pursuant to the Teleflex Incorporated 2023 Stock Incentive Plan. Award vests 100% on the one-year anniversary of the grant date; provided, however, if the reporting person does not stand for re-election to the issuer's board of directors (the "Board") at the issuer's 2027 annual meeting of stockholders (the "2027 Annual Meeting"), the award will vest on the earlier of the one-year anniversary of the grant date and the date of the 2027 Annual Meeting, so long as such meeting is held at least 50 weeks after the issuer's 2026 annual meeting of stockholders (the "2026 Annual Meeting"). |
| Stock Option / (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $129.71 · Expires 2036-05-15 | Direct | 2,397 |
Reported balance
After 2026-05-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-15 · Grant · Acquired 2,397 · Balance 2,397 F2: Stock Option Award vests 100% on the one-year anniversary of the grant date; provided, however, if the reporting person does not stand for re-election to the Board at the 2027 Annual Meeting, the award will vest on the earlier of the one-year anniversary of the grant date and the date of the 2027 Annual Meeting, so long as such meeting is held at least 50 weeks after the 2026 Annual Meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted Stock Unit Award granted pursuant to the Teleflex Incorporated 2023 Stock Incentive Plan. Award vests 100% on the one-year anniversary of the grant date; provided, however, if the reporting person does not stand for re-election to the issuer's board of directors (the "Board") at the issuer's 2027 annual meeting of stockholders (the "2027 Annual Meeting"), the award will vest on the earlier of the one-year anniversary of the grant date and the date of the 2027 Annual Meeting, so long as such meeting is held at least 50 weeks after the issuer's 2026 annual meeting of stockholders (the "2026 Annual Meeting").
F2: Stock Option Award vests 100% on the one-year anniversary of the grant date; provided, however, if the reporting person does not stand for re-election to the Board at the 2027 Annual Meeting, the award will vest on the earlier of the one-year anniversary of the grant date and the date of the 2027 Annual Meeting, so long as such meeting is held at least 50 weeks after the 2026 Annual Meeting.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 10, 2026 Filed Sep 14, 2026 22:38 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,200 | $240.94 | $289,128.00 |
DisclosureSEC source: 0001783908-26-000022 · edgardoc.xml · nonDerivative · entry 1 Patil Neena M · CIK 0001783908 · EVP & Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,671 F1 · kind: This transaction was made pursuant to a plan adopted by the reporting person on February 26, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 22:09 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 2,678 | $237.72 | $636,614.16 |
DisclosureSEC source: 0001783908-26-000019 · edgardoc.xml · nonDerivative · entry 1 Patil Neena M · CIK 0001783908 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,871 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 20:14 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,200 | $231.83 | $278,196.00 |
DisclosureSEC source: 0001783908-26-000017 · edgardoc.xml · nonDerivative · entry 1 Patil Neena M · CIK 0001783908 · EVP & Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,549 F1 · kind: This transaction was made pursuant to a plan adopted by the reporting person on February 26, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. F2 · balance_after: The Reporting Person acquired 123 ordinary shares under a Section 423 Employee Stock Purchase Plan on May 29, 2026. Read SEC document |
| May 28, 2026 Filed Jun 1, 2026 20:09 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,192 | $236.97 | $282,468.24 |
DisclosureSEC source: 0001783908-26-000014 · edgardoc.xml · nonDerivative · entry 1 Patil Neena M · CIK 0001783908 · EVP & Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,626 F1 · kind: This transaction was made pursuant to a plan adopted by the reporting person on February 26, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. Read SEC document |
| May 15, 2026 Filed May 20, 2026 00:56 UTC | TELEFLEX INC TFX · Entity 3798 | GrantStock Option / (Right to Buy) · Derivative | 2,397 | $0.00 Strike: $129.71 | $0.00 |
DisclosureSEC source: 0001783908-26-000012 · wk-form4_1779238609.xml · derivative · entry 2 Patil Neena M · CIK 0001783908 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,397 Underlying: Common Stock · 2,397 shares Expires 2036-05-15 F2 · derivative.exercise_date: Stock Option Award vests 100% on the one-year anniversary of the grant date; provided, however, if the reporting person does not stand for re-election to the Board at the 2027 Annual Meeting, the award will vest on the earlier of the one-year anniversary of the grant date and the date of the 2027 Annual Meeting, so long as such meeting is held at least 50 weeks after the 2026 Annual Meeting. Read SEC document |
| May 15, 2026 Filed May 20, 2026 00:56 UTC | TELEFLEX INC TFX · Entity 3798 | GrantCommon Stock | 1,090 | $0.00 | $0.00 |
DisclosureSEC source: 0001783908-26-000012 · wk-form4_1779238609.xml · nonDerivative · entry 1 Patil Neena M · CIK 0001783908 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,716 F1 · kind: Restricted Stock Unit Award granted pursuant to the Teleflex Incorporated 2023 Stock Incentive Plan. Award vests 100% on the one-year anniversary of the grant date; provided, however, if the reporting person does not stand for re-election to the issuer's board of directors (the "Board") at the issuer's 2027 annual meeting of stockholders (the "2027 Annual Meeting"), the award will vest on the earlier of the one-year anniversary of the grant date and the date of the 2027 Annual Meeting, so long as such meeting is held at least 50 weeks after the issuer's 2026 annual meeting of stockholders (the "2026 Annual Meeting"). Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 21:07 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 5,000 | $188.69 | $943,450.00 |
DisclosureSEC source: 0001783908-26-000010 · edgardoc.xml · nonDerivative · entry 1 Patil Neena M · CIK 0001783908 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,818 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 22:06 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 27,084 | $0.00 Strike: $137.12 | $0.00 |
DisclosureSEC source: 0001783908-26-000007 · edgardoc.xml · derivative · entry 20 Patil Neena M · CIK 0001783908 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 27,084 shares Expires 2029-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F14 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of July 29, 2019, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 22:06 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 20,125 | $0.00 Strike: $113.10 | $0.00 |
DisclosureSEC source: 0001783908-26-000007 · edgardoc.xml · derivative · entry 19 Patil Neena M · CIK 0001783908 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 20,125 shares Expires 2030-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F13 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 27, 2020, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 22:06 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 2,916 | $0.00 Strike: $137.12 | $0.00 |
DisclosureSEC source: 0001783908-26-000007 · edgardoc.xml · derivative · entry 18 Patil Neena M · CIK 0001783908 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,916 shares Expires 2029-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F14 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of July 29, 2019, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 22:06 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 875 | $0.00 Strike: $113.10 | $0.00 |
DisclosureSEC source: 0001783908-26-000007 · edgardoc.xml · derivative · entry 17 Patil Neena M · CIK 0001783908 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 875 shares Expires 2030-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F13 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 27, 2020, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 22:06 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 197 | $193.60 | $38,138.85 |
DisclosureSEC source: 0001783908-26-000007 · edgardoc.xml · nonDerivative · entry 16 Patil Neena M · CIK 0001783908 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,818 F12 · price: Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $193.5300 to $193.6700. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 22:06 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,009 | $192.79 | $194,526.62 |
DisclosureSEC source: 0001783908-26-000007 · edgardoc.xml · nonDerivative · entry 15 Patil Neena M · CIK 0001783908 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,015 F11 · price: Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $192.4600 to $193.4500. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 22:06 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,784 | $191.88 | $342,311.96 |
DisclosureSEC source: 0001783908-26-000007 · edgardoc.xml · nonDerivative · entry 14 Patil Neena M · CIK 0001783908 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,024 F10 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $191.4750 to $192.4300. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 22:06 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 549 | $190.80 | $104,747.17 |
DisclosureSEC source: 0001783908-26-000007 · edgardoc.xml · nonDerivative · entry 13 Patil Neena M · CIK 0001783908 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,808 F9 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $190.4100 to $191.2150. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 22:06 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,061 | $190.00 | $201,593.71 |
DisclosureSEC source: 0001783908-26-000007 · edgardoc.xml · nonDerivative · entry 12 Patil Neena M · CIK 0001783908 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,357 F8 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $189.395 to $190.3700. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 22:06 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 3,523 | $193.58 | $681,993.26 |
DisclosureSEC source: 0001783908-26-000007 · edgardoc.xml · nonDerivative · entry 11 Patil Neena M · CIK 0001783908 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,418 F7 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $193.2900 to $193.8400. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 22:06 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 11,529 | $191.65 | $2,209,480.97 |
DisclosureSEC source: 0001783908-26-000007 · edgardoc.xml · nonDerivative · entry 10 Patil Neena M · CIK 0001783908 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,941 F6 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $191.3200 to $192.0600. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 22:06 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 10,079 | $0.00 | $0.00 |
DisclosureSEC source: 0001783908-26-000007 · edgardoc.xml · nonDerivative · entry 9 Patil Neena M · CIK 0001783908 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,470 F5 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2026, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 22:06 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 2,916 | $189.81 | $553,490.92 |
DisclosureSEC source: 0001783908-26-000007 · edgardoc.xml · nonDerivative · entry 8 Patil Neena M · CIK 0001783908 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,391 F4 · price: Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $189.7300 to $189.9150. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 22:06 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionOrdinary Shares | 2,916 | $137.12 | $399,841.92 |
DisclosureSEC source: 0001783908-26-000007 · edgardoc.xml · nonDerivative · entry 7 Patil Neena M · CIK 0001783908 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,307 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 22:06 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 15,555 | $190.28 | $2,959,806.96 |
DisclosureSEC source: 0001783908-26-000007 · edgardoc.xml · nonDerivative · entry 6 Patil Neena M · CIK 0001783908 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,391 F3 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $189.9150 to $190.9000. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 22:06 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionOrdinary Shares | 27,084 | $137.12 | $3,713,758.08 |
DisclosureSEC source: 0001783908-26-000007 · edgardoc.xml · nonDerivative · entry 5 Patil Neena M · CIK 0001783908 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,946 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 22:06 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 875 | $192.07 | $168,056.96 |
DisclosureSEC source: 0001783908-26-000007 · edgardoc.xml · nonDerivative · entry 4 Patil Neena M · CIK 0001783908 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,862 F2 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $192.0600 to $192.1100. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 22:06 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionOrdinary Shares | 875 | $113.10 | $98,962.50 |
DisclosureSEC source: 0001783908-26-000007 · edgardoc.xml · nonDerivative · entry 3 Patil Neena M · CIK 0001783908 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,737 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 22:06 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 16,602 | $192.53 | $3,196,334.91 |
DisclosureSEC source: 0001783908-26-000007 · edgardoc.xml · nonDerivative · entry 2 Patil Neena M · CIK 0001783908 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,862 F1 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $192.1100 to $193.0100. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 22:06 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionOrdinary Shares | 20,125 | $113.10 | $2,276,137.50 |
DisclosureSEC source: 0001783908-26-000007 · edgardoc.xml · nonDerivative · entry 1 Patil Neena M · CIK 0001783908 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,464 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 16, 2026 Filed Jan 22, 2026 01:36 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Disposition to issuerOrdinary Shares | 3,275 | $171.16 | $560,549.00 |
DisclosureSEC source: 0001783908-26-000005 · edgardoc.xml · nonDerivative · entry 2 Patil Neena M · CIK 0001783908 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,339 F3 · kind: Shares withheld from the vesting and distribution of performance share awards to satisfy the reporting person's tax obligations. Read SEC document |
| January 16, 2026 Filed Jan 22, 2026 01:36 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 8,852 | $0.00 | $0.00 |
DisclosureSEC source: 0001783908-26-000005 · edgardoc.xml · nonDerivative · entry 1 Patil Neena M · CIK 0001783908 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,614 F1 · kind: Represents ordinary shares of the Issuer delivered pursuant to the terms of performance share awards made to the reporting person on March 3, 2023. The performance-based vesting requirements applicable to such awards were satisfied on January 16, 2026, which represents the date on which the level of performance attained was certified. F2 · balance_after: The Reporting Person acquired 116 ordinary shares on May 30, 2025 and 120 ordinary shares on November 28, 2025 under a Section 423 Employee Stock Purchase Plan. Read SEC document |
| May 09, 2025 Filed May 13, 2025 21:03 UTC | TELEFLEX INC TFX · Entity 3798 | GrantStock Option / (Right to Buy) · Derivative | 2,226 | $0.00 Strike: $125.11 | $0.00 |
DisclosureSEC source: 0000096943-25-000093 · wk-form4_1747170179.xml · derivative · entry 2 Patil Neena M · CIK 0001783908 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,226 Underlying: Common Stock · 2,226 shares Expires 2035-05-09 F2 · derivative.exercise_date: If the reporting person does not stand for re-election to the issuer's board of directors at the issuer's 2026 annual meeting of stockholders (the "2026 Annual Meeting"), the award will vest on the earlier of the one-year anniversary of the grant date and the date of the 2026 Annual Meeting, so long as such meeting is held at least 50 weeks after the issuer's 2025 annual meeting of stockholders. Read SEC document |
| May 09, 2025 Filed May 13, 2025 21:03 UTC | TELEFLEX INC TFX · Entity 3798 | GrantCommon Stock | 1,051 | $0.00 | $0.00 |
DisclosureSEC source: 0000096943-25-000093 · wk-form4_1747170179.xml · nonDerivative · entry 1 Patil Neena M · CIK 0001783908 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,626 F1 · kind: Restricted Stock Unit Award granted pursuant to the Teleflex Incorporated 2023 Stock Incentive Plan. Award vests on the one-year anniversary of the grant date; provided, however, if the reporting person does not stand for re-election to the issuer's board of directors at the issuer's 2026 annual meeting of stockholders (the "2026 Annual Meeting"), the award will vest on the earlier of the one-year anniversary of the grant date and the date of the 2026 Annual Meeting, so long as such meeting is held at least 50 weeks after the issuer's 2025 annual meeting of stockholders. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 23:57 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Disposition to issuerOrdinary Shares | 4,088 | $138.95 | $568,027.60 |
DisclosureSEC source: 0001765581-25-000028 · edgardoc.xml · nonDerivative · entry 1 Patil Neena M · CIK 0001783908 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,526 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| February 27, 2025 Filed Mar 4, 2025 00:18 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 5,778 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-25-000008 · edgardoc.xml · nonDerivative · entry 3 Patil Neena M · CIK 0001783908 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,614 F3 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units will vest in full on June 30, 2026. Read SEC document |
| February 27, 2025 Filed Mar 4, 2025 00:18 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 12,518 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-25-000008 · edgardoc.xml · nonDerivative · entry 2 Patil Neena M · CIK 0001783908 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,836 F2 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2025, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
| February 27, 2025 Filed Mar 4, 2025 00:18 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 3,800 | $144.87 | $550,506.00 |
DisclosureSEC source: 0001765581-25-000008 · edgardoc.xml · nonDerivative · entry 1 Patil Neena M · CIK 0001783908 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,318 F1 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $144.81 to $144.88. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| January 17, 2025 Filed Jan 22, 2025 23:43 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 1,905 | $122.62 | $233,591.10 |
DisclosureSEC source: 0001805688-25-000005 · edgardoc.xml · nonDerivative · entry 2 Patil Neena M · CIK 0001783908 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,118 F3 · kind: Shares to be withheld from the vesting and distribution of performance award shares to satisfy the reporting person's tax obligations. Read SEC document |
| January 17, 2025 Filed Jan 22, 2025 23:43 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 5,864 | $0.00 | $0.00 |
DisclosureSEC source: 0001805688-25-000005 · edgardoc.xml · nonDerivative · entry 1 Patil Neena M · CIK 0001783908 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,023 F1 · kind: Represents ordinary shares of Jazz Pharamceuticals that will be delivered pursuant to the terms of performance share awards made to the reporting person on March 3, 2022. The performance-based vesting requirements applicable to such awards were satisfied on January 17, 2025, which represents the date on which the level of performance attained was certified. F2 · balance_after: The Reporting Person acquired 111 ordinary shares under a Section 423 Employee Stock Purchase Plan on November 29, 2024. Read SEC document |
| November 08, 2024 Filed Nov 13, 2024 22:44 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 3,700 | $123.41 | $456,617.00 |
DisclosureSEC source: 0001765581-24-000088 · edgardoc.xml · nonDerivative · entry 1 Patil Neena M · CIK 0001783908 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,048 F1 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $123.31 to $123.51. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F2 · balance_after: Includes 119 ordinary shares acquired on May 31, 2024 under a Section 423 Employee Stock Purchase Plan. Read SEC document |
| May 07, 2024 Filed May 9, 2024 22:57 UTC | TELEFLEX INC TFX · Entity 3798 | GrantStock Option / (Right to Buy) · Derivative | 1,349 | $0.00 Strike: $201.52 | $0.00 |
DisclosureSEC source: 0000096943-24-000082 · wk-form4_1715295415.xml · derivative · entry 2 Patil Neena M · CIK 0001783908 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,349 Underlying: Common Stock · 1,349 shares Expires 2034-05-07 F2 · derivative.exercise_date: If the reporting person does not stand for re-election to the issuer's board of directors at the issuer's 2025 annual meeting of stockholders (the "2025 Annual Meeting"), the award will vest on the earlier of the one-year anniversary of the grant date and the date of the 2025 Annual Meeting, so long as such meeting is held at least 50 weeks after the issuer's 2024 annual meeting of stockholders. Read SEC document |
| May 07, 2024 Filed May 9, 2024 22:57 UTC | TELEFLEX INC TFX · Entity 3798 | GrantCommon Stock | 649 | $0.00 | $0.00 |
DisclosureSEC source: 0000096943-24-000082 · wk-form4_1715295415.xml · nonDerivative · entry 1 Patil Neena M · CIK 0001783908 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,575 F1 · kind: Restricted Stock Unit Award granted pursuant to the Teleflex Incorporated 2023 Stock Incentive Plan. Award vests on the one-year anniversary of the grant date; provided, however, if the reporting person does not stand for re-election to the issuer's board of directors at the issuer's 2025 annual meeting of stockholders (the "2025 Annual Meeting"), the award will vest on the earlier of the one-year anniversary of the grant date and the date of the 2025 Annual Meeting, so long as such meeting is held at least 50 weeks after the issuer's 2024 annual meeting of stockholders. Read SEC document |
| May 03, 2024 Filed May 7, 2024 21:31 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 5,000 | $109.65 | $548,250.00 |
DisclosureSEC source: 0001765581-24-000042 · edgardoc.xml · nonDerivative · entry 1 Patil Neena M · CIK 0001783908 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,629 F1 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $109.58 to $109.77. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| March 05, 2024 Filed Mar 8, 2024 02:48 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 3,432 | $117.53 | $403,362.96 |
DisclosureSEC source: 0001765581-24-000033 · edgardoc.xml · nonDerivative · entry 1 Patil Neena M · CIK 0001783908 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,629 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 00:50 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 12,348 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-24-000020 · edgardoc.xml · nonDerivative · entry 1 Patil Neena M · CIK 0001783908 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,061 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2024, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
| January 17, 2024 Filed Jan 19, 2024 23:28 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 1,656 | $119.13 | $197,279.28 |
DisclosureSEC source: 0001784606-24-000010 · edgardoc.xml · nonDerivative · entry 2 Patil Neena M · CIK 0001783908 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,713 F3 · kind: Shares to be withheld from the vesting and distribution of performance award shares to satisfy the reporting person's tax obligations. Read SEC document |
| January 17, 2024 Filed Jan 19, 2024 23:28 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 5,087 | $0.00 | $0.00 |
DisclosureSEC source: 0001784606-24-000010 · edgardoc.xml · nonDerivative · entry 1 Patil Neena M · CIK 0001783908 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,369 F1 · kind: Represents ordinary shares of Jazz Pharamceuticals that will be delivered pursuant to the terms of performance share awards made to the reporting person on May 5, 2021. The performance-based vesting requirements applicable to such awards were satisfied on January 17, 2024, which represents the date on which the level of performance attained was certified. F2 · balance_after: The Reporting Person acquired 96 ordinary shares under a Section 423 Employee Stock Purchase Plan on November 30, 2023. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 21:09 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,500 | $144.25 | $216,375.00 |
DisclosureSEC source: 0001765581-23-000104 · edgardoc.xml · nonDerivative · entry 1 Patil Neena M · CIK 0001783908 · EVP & Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,186 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 2, 2023. Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 21:21 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 750 | $139.59 | $104,694.98 |
DisclosureSEC source: 0001765581-23-000100 · edgardoc.xml · nonDerivative · entry 1 Patil Neena M · CIK 0001783908 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,686 F1 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $139.56 to $139.63. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| August 07, 2023 Filed Aug 9, 2023 20:19 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Disposition to issuerOrdinary Shares | 1,390 | $131.51 | $182,798.90 |
DisclosureSEC source: 0001765581-23-000054 · edgardoc.xml · nonDerivative · entry 1 Patil Neena M · CIK 0001783908 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,436 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| June 01, 2023 Filed Jun 6, 2023 00:24 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 74 | $128.02 | $9,473.11 |
DisclosureSEC source: 0001765581-23-000044 · edgardoc.xml · nonDerivative · entry 2 Patil Neena M · CIK 0001783908 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,826 Read SEC document |
| June 01, 2023 Filed Jun 6, 2023 00:24 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,526 | $127.98 | $195,290.00 |
DisclosureSEC source: 0001765581-23-000044 · edgardoc.xml · nonDerivative · entry 1 Patil Neena M · CIK 0001783908 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,900 F1 · price: Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $127.91 to $128.015. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F2 · balance_after: Includes 87 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on May 31, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.